Factor V Deficiency.
Stoj KM, Pierro J.
2024 May 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Structural Model for Factor X Inhibition of IgM and Complement-Mediated Neutralization of Adenovirus.
Wagner N, Shayakhmetov DM, Stewart PL.
Viruses. 2023 Jun 9;15(6):1343. doi: 10.3390/v15061343.
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIalpha.
van Doorn P, Rosing J, Campello E, Middeldorp S, Simioni P, Meijers JCM, Hackeng TM, Castoldi E.
Thromb Haemost. 2020 Jan;120(1):55-64. doi: 10.1055/s-0039-1700516. Epub 2019 Nov 8.
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa.
Wu S, Wang T, Li J, Zhang Z, Li C, Xiao S, He J, Wang X, Hu Z, Wang X, Zheng S, Liang X, Chen G, Li Y, Li X, Zhan Y, Zou Q, Jiang H, Zheng Q, Ban L, Liu H, Fang Y.
Expert Opin Investig Drugs. 2023 Jul-Dec;32(11):1085-1094. doi: 10.1080/13543784.2023.2283024. Epub 2023 Nov 24.
Presence and activity of Fibrinogen like protein 2 in platelets.
Cherny I, Hasin P, Philosoph LK, Shahal-Zimra Y, Gurion R, Rabizadeh E.
PLoS One. 2023 May 18;18(5):e0285735. doi: 10.1371/journal.pone.0285735. eCollection 2023.
Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding.
Jankowski W, Surov SS, Hernandez NE, Rawal A, Battistel M, Freedberg D, Ovanesov MV, Sauna ZE.
Nat Commun. 2024 May 9;15(1):3912. doi: 10.1038/s41467-024-48278-1.
Performance of a Qualitative Point-of-Care Strip Test to Detect DOAC Exposure at the Emergency Department: A Cohort-Type Cross-Sectional Diagnostic Accuracy Study.
Merrelaar AE, Bögl MS, Buchtele N, Merrelaar M, Herkner H, Schoergenhofer C, Harenberg J, Douxfils J, Siriez R, Jilma B, Spiel AO, Schwameis M.
Thromb Haemost. 2022 Oct;122(10):1723-1731. doi: 10.1055/s-0042-1750327. Epub 2022 Jul 4.
Effects of temperature, pH, and inhibitors on the procoagulant characterization of FIa, a factor X activator from the venom of Daboia russellii siamensis (Myanmar).
Sun H, Ma H, He G, Chen J, Qiu P, Yan G.
Arch Pharm Res. 2010 Jul;33(7):1043-8. doi: 10.1007/s12272-010-0710-7. Epub 2010 Jul 27.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA.
Circulation. 2002 May 21;105(20):2385-91. doi: 10.1161/01.cir.0000016351.12759.52.
A sensitive, accurate assay for extrinsic pathway inhibitor (EPI) activity in rabbit plasma: paradoxical effect of excess exogenous factor X.
Warr TA, Rao LV, Rapaport SI.
Thromb Res. 1990 Aug 15;59(4):773-82. doi: 10.1016/0049-3848(90)90058-k.
